Yellow Fever Vaccine (Live Attenuated)
Treatment for Yellow Fever
Typical Dosage: 0.5 mL subcutaneous injection
Effectiveness
98%
Safety Score
78%
Clinical Trials
14
Participants
100M
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
78
DangerousModerateSafe
Treatment Details
Dosage Range
0.5 mL subcutaneous injection
Time to Effect
10 days
Treatment Duration
Single dose (lifelong immunity)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
118(Treat 118 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
100000(Treat 100000 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$20
Side Effect Mgmt:$5
Total Annual:$225
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$207/QALY
QALYs Gained
0.25
Prescription Access Economics
Physician Visit Cost
$75/year
Time Cost
$30/year
Travel + wait time
Insurance Admin Cost
$15/year
Prior auth, claims
Rx Price
$200/year
Risk Assessment
Misuse Risk
LOWYellow Fever Vaccine (Live Attenuated) Outcomes
for Yellow Fever
Efficacy Outcomes
Overall Effectiveness
+98%
Response Rate
+98%
Common Side Effects
Injection site pain/tenderness
+20%
Headache
+8%
Muscle aches
+7%
Low-grade fever
+3%
Hypersensitivity/allergic reaction (rare)
+0.05%
Viscerotropic disease (YEL-AVD, very rare, serious)
+0.0001%
Neurotropic disease (YEL-AND, very rare, serious)
+0.0001%
Sources:
Active Clinical Trials
3 active trials recruiting for Yellow Fever Vaccine (Live Attenuated) in Yellow Fever
A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population
NCT07103148RECRUITINGPHASE3
2.44K participants
INTERVENTIONAL
San Pedro Sula, Honduras +12 more
Started: Jul 11, 2025
Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months
NCT06815835NOT YET RECRUITINGPHASE3
1.53K participants
INTERVENTIONAL
Dhaka, Bangladesh
Started: Apr 1, 2025
Improving Vaccine Protection for Adults
NCT07527247RECRUITINGPHASE2
40 participants
INTERVENTIONAL
Singapore, Singapore
Started: Nov 6, 2025
Completed Clinical Trials
9 completed trials for Yellow Fever Vaccine (Live Attenuated) in Yellow Fever
Yellow Fever Vaccine on Statin/ Non Statin Subjects
NCT03116802COMPLETEDPHASE2
37 participants
INTERVENTIONAL
Singapore, Singapore
Started: Mar 8, 2017
Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old
NCT03725618COMPLETEDPHASE4
1.79K participants
INTERVENTIONAL
Atlanta, United States
Started: Nov 1, 2018
Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)
NCT00982137COMPLETEDPHASE2
108 participants
INTERVENTIONAL
Herston, Australia
Started: Jul 1, 2004
Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine
NCT01488890COMPLETEDPHASE2
390 participants
INTERVENTIONAL
Alabaster, United States +6 more
Started: Dec 6, 2011
Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea
NCT03541694COMPLETED
622 participants
OBSERVATIONAL
Seoul, South Korea
Started: Apr 11, 2018
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL
NCT05421611COMPLETEDPHASE3
1.82K participants
INTERVENTIONAL
Kisumu, Kenya +1 more
Started: May 11, 2023
Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
NCT01436396COMPLETEDPHASE3
792 participants
INTERVENTIONAL
Cali, Colombia +1 more
Started: Sep 7, 2011
Yellow Fever Virus Vaccine and Immune Globulin Study
NCT00254826COMPLETEDPHASE1
80 participants
INTERVENTIONAL
Decatur, United States
Started: Jun 1, 2006
Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.
NCT02699099COMPLETEDPHASE3
699 participants
INTERVENTIONAL
Kintampo, Ghana +1 more
Started: May 10, 2017